Man Group PLC Cassava Sciences Inc Transaction History

Man Group PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $227,808 - $370,713	-6,988 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $119,355 - $295,093	3,246 Added 86.75%	6,988 $305,000
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $61,849 - $200,244	-1,480 Reduced 28.34%	3,742 $232,000
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $167,887 - $468,517	5,222 New	5,222 $447,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.